Any current/future new fundraising through debt or equity?

For the current CapEx plans (INR 300-350 crores in FY23), the company has sufficient funding lines and arrangements in place. Management is not currently planning any rights issue or equity fundraising. Future CapEx funding options will be evaluated based on growth strategy, order pipeline, and other factors. Debt or internal accruals are the preferred modes of funding for upcoming CapEx. Management will review all funding options, including possible debt, as they move forward depending on requirements.

Any current/future capex/capital investment/strategic investment?

FY23 CapEx guidance is INR 300 crores to INR 350 crores, on track to deliver within this range. CapEx focus areas include: - New R&D center (around INR 110 crores) - New multipurpose plant (around INR 100 crores) - Sustainability initiatives and acquisition of new land - Debottlenecking of the existing herbicide plant Investment strategy includes quickly utilizing existing herbicide plant capacity and scaling through debottlenecking and additional capacity expansion. Future CapEx plans will be discussed next financial year; funding options include internal accruals and de

Future growth expectations in sales/revenue/volumes?

Volume growth in Q2 FY23 was strong at 38% year-on-year, with 11% ahead in H1 FY23. The company aims to increase CMO segment revenue share from around 11% in H1 FY23 towards 20-25% in the near short-term. The herbicide plant commercialized last year is targeted to be utilized at 20-25% last year, 55-60% this year, and at full utilization by end of the third year. Astec plans to commercialize at least two new CMO products annually, expanding its technology platforms beyond triazole chemistry. The company is focused on continuing volume growth through new product introductions, backward integrat

Future growth expectations in earnings/operating earnings/profits/EPS?

Astec LifeSciences demonstrated strong topline growth with total income rising 97% in Q2 FY23 and 68% in H1 FY23, indicating robust volume and realization gains, especially in export markets. EBITDA margin contracted due to raw material cost inflation and fixed overheads but company aims to normalize margins as macros stabilize. CMO segment revenues have grown to 8% of total revenues in Q2 FY23 from 4% last year, with targeted expansion in herbicide and triazole chemistry portfolios. Company plans to commercialize at least two new R&D projects annually, enhancing future earnings potential. Cap

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details about the current or expected order book or pending orders for Astec LifeSciences Limited. However, management mentioned that future CapEx decisions will depend on the growth strategy and order pipeline, indicating that order inflow is being monitored actively. The company is also developing its CMO segment with a good pipeline building up, especially focusing on triazole and herbicide chemistries. They are targeting to commercialize about two new CDMO products every year, indicating a steady inflow of contract manufacturing orders. Backward int

Astec LifesciencQ2 FY23Fertilizers & Agrochemicals

Astec Lifescienc Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.55Market Cap: ₹1.2K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Volume growth in Q2 FY23 was strong at 38% year-on-year, with 11% ahead in H1 FY23.
The company aims to increase CMO segment revenue share from around 11% in H1 FY23 towards 20-25% in the near short-term.
The herbicide plant commercialized last year is targeted to be utilized at 20-25% last year, 55-60% this year, and at full utilization by end of the third year.
Astec plans to commercialize at least two new CMO products annually, expanding its technology platforms beyond triazole chemistry.
The company is focused on continuing volume growth through new product introductions, backward integration, and capacity debottlenecking.
Exports are a key growth driver, having grown by 162% in H1 FY23, comprising 69% of total revenues in Q2.
Medium-term CapEx plans will support growth, with investments funded by internal accruals and debt as needed.

Margin guidance

Category 3

Astec LifeSciences demonstrated strong topline growth with total income rising 97% in Q2 FY23 and 68% in H1 FY23, indicating robust volume and realization gains, especially in export markets.
EBITDA margin contracted due to raw material cost inflation and fixed overheads but company aims to normalize margins as macros stabilize.
CMO segment revenues have grown to 8% of total revenues in Q2 FY23 from 4% last year, with targeted expansion in herbicide and triazole chemistry portfolios.
Company plans to commercialize at least two new R&D projects annually, enhancing future earnings potential.
CapEx guidance of INR 300-350 crores for FY23 supports capacity expansion, expected to drive higher asset turns (1.5x to 1.7x) and scale revenue/profitability over 3-4 years.
Management remains cautiously optimistic on margin improvement but acknowledges near-term pressures from RM inflation.
Overall, growth in operating earnings/EPS expected from volume growth, expanded product portfolio, and increased utilization of new capacity over medium term.

See what Astec Lifescienc management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

For the current CapEx plans (INR 300-350 crores in FY23), the company has sufficient funding lines and arrangements in place.
Management is not currently planning any rights issue or equity fundraising.
Future CapEx funding options will be evaluated based on growth strategy, order pipeline, and other factors.
Debt or internal accruals are the preferred modes of funding for upcoming CapEx.
Management will review all funding options, including possible debt, as they move forward depending on requirements.

Order book

Yes

The transcript does not provide explicit details about the current or expected order book or pending orders for Astec LifeSciences Limited.
However, management mentioned that future CapEx decisions will depend on the growth strategy and order pipeline, indicating that order inflow is being monitored actively.
The company is also developing its CMO segment with a good pipeline building up, especially focusing on triazole and herbicide chemistries.
They are targeting to commercialize about two new CDMO products every year, indicating a steady inflow of contract manufacturing orders.
Backward integration and strategic sourcing are being leveraged to support manufacturing efficiency and order fulfillment.
Overall, the order pipeline appears positive but specific quantitative order book values or pending orders are not disclosed in this call transcript.

See what Astec Lifescienc management said on order book — free account, 30 seconds.

Capex plans

Yes

FY23 CapEx guidance is INR 300 crores to INR 350 crores, on track to deliver within this range.
CapEx focus areas include:
- New R&D center (around INR 110 crores)
- New multipurpose plant (around INR 100 crores)
- Sustainability initiatives and acquisition of new land
- Debottlenecking of the existing herbicide plant
Investment strategy includes quickly utilizing existing herbicide plant capacity and scaling through debottlenecking and additional capacity expansion.
Future CapEx plans will be discussed next financial year; funding options include internal accruals and debt, with all options under review.
Currently, sufficient funding lines in place; no immediate plans for rights issue or fund raise but may consider as per future needs.
CapEx aligned with growth strategy including expanding product portfolio and enhancing CMO capacities.

Track Astec Lifescienc — get its next earnings analysis in your feed

How does Astec Lifescienc rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisAstec Lifescienc

Rev 3Mar 3

See where Astec Lifescienc sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Astec Lifescienc rank in Fertilizers & Agrochemicals?

Compare Astec Lifescienc against every Fertilizers & Agrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Astec Lifescienc's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Best Agrolife Ltd (Q2 FY27)
Revenue from operations for Q2 FY27 is ₹407 crore, reflecting a year-on-year decline of 21%. Key results statement takeaways from Best Agrolife Ltd's Q2 FY27 ea
Dhanuka Agritech Ltd (Q2 FY27)
657.51 Crores . Key investor presentation takeaways from Dhanuka Agritech Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Sharda Cropchem Ltd (Q2 FY27)
1,051.7 Cr, up 13% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Sharda Cropchem Ltd's Q2 FY27 investor presentation — and how it ranks against sec
Paradeep Phosphates Ltd (Q2 FY27)
Revenue from operations for the quarter ended 30 September 2026: Rs 7,164.06 crores . Key results statement takeaways from Paradeep Phosphates Ltd's Q2 FY27 ear

Compare:vs Coromandel Inter vs F A C T vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Astec Lifescienc Q2 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Astec Lifescienc rank in Fertilizers & Agrochemicals?

Continue your research

What Astec Lifescienc's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season